Market Place
Sourcing Support
Catabasis Top-Line Results for the Ph3 PolarisDMD Trial of Edasalonexent
27 Oct 2020 //
BUSINESSWIRE
Catabasis Pharma to Present in Virtual 25th International Congress of WMS
23 Sep 2020 //
BUSINESSWIRE
Catabasis Pharma Presents Edasalonexent, a Potential Foundational Therapy
12 May 2020 //
BIOSPACE
Catabasis Pharma Presents Edasalonexent, a Potential Foundational Therapy
12 May 2020 //
BUSINESSWIRE
Catabasis Pharma Announces the Phase 3 PolarisDMD Trial of Edasalonexent
30 Sep 2019 //
BIOSPACE
Catabasis Pharmaceuticals Announces Pricing of $20 Million Public Offering
06 Feb 2019 //
BUSINESSWIRE
Catabasis Pharms Initiates Ph 3 Polaris DMD Clinical Trial for Edasalonexent
25 Sep 2018 //
BUSINESSWIRE
Catabasis Pharma Announces Plans for Edasalonexent Ph 3 POLARIS DMD Trial
09 Jul 2018 //
BUSINESSWIRE
Catabasis Pharma`s cholesterol drug fails mid-stage study
07 Jun 2016 //
REUTERS
EC grants Orphan Medicinal Product status to Catabasis Pharmaceutical CAT-1004
27 Oct 2015 //
PHARMABIZ
PPMD inks collaboration with Catabasis Pharma on CAT-1004 development to treat Duchenne
15 Dec 2014 //
PHARMABIZ
Copyright © 2025 LePro PharmaCompass OPC Private Limited, All rights reserved.